vs
Side-by-side financial comparison of C & F FINANCIAL CORP (CFFI) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
C & F FINANCIAL CORP is the larger business by last-quarter revenue ($35.9M vs $18.6M, roughly 1.9× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 18.7%, a 47.1% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 12.0%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 8.2%).
Sun Life Financial Inc. is a Canadian financial services company headquartered in Toronto, Ontario. Founded in 1865, it operates internationally in life insurance, wealth management, and asset management. As of 2024, the company manages over CAD$1.3 trillion in assets and serves clients in Canada, the United States, Asia, and other markets.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
CFFI vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.9M | $18.6M |
| Net Profit | $6.7M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 22.6% | 56.3% |
| Net Margin | 18.7% | 65.7% |
| Revenue YoY | 12.0% | 1808.5% |
| Net Profit YoY | 11.0% | 376.5% |
| EPS (diluted) | $2.08 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.9M | $18.6M | ||
| Q3 25 | $36.0M | $334.0K | ||
| Q2 25 | $36.4M | $1.4M | ||
| Q1 25 | $32.6M | $257.0K | ||
| Q4 24 | $32.0M | $977.0K | ||
| Q3 24 | $33.5M | $660.0K | ||
| Q2 24 | $31.2M | $736.0K | ||
| Q1 24 | $30.6M | $1.4M |
| Q4 25 | $6.7M | $12.3M | ||
| Q3 25 | $7.1M | $-8.6M | ||
| Q2 25 | $7.7M | $-6.9M | ||
| Q1 25 | $5.4M | $-5.4M | ||
| Q4 24 | $6.0M | — | ||
| Q3 24 | $5.4M | $-2.8M | ||
| Q2 24 | $5.0M | $-14.5M | ||
| Q1 24 | $3.4M | $411.0K |
| Q4 25 | 22.6% | 56.3% | ||
| Q3 25 | 24.5% | -2516.5% | ||
| Q2 25 | 26.5% | -701.0% | ||
| Q1 25 | 20.0% | -3350.2% | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 19.9% | -1563.6% | ||
| Q2 24 | 20.0% | -1255.0% | ||
| Q1 24 | 13.1% | -692.5% |
| Q4 25 | 18.7% | 65.7% | ||
| Q3 25 | 19.6% | -2572.2% | ||
| Q2 25 | 21.2% | -504.8% | ||
| Q1 25 | 16.5% | -2097.7% | ||
| Q4 24 | 18.8% | — | ||
| Q3 24 | 16.1% | -425.5% | ||
| Q2 24 | 16.1% | -1964.4% | ||
| Q1 24 | 11.1% | 29.9% |
| Q4 25 | $2.08 | $0.25 | ||
| Q3 25 | $2.18 | $-0.17 | ||
| Q2 25 | $2.37 | $-0.14 | ||
| Q1 25 | $1.66 | $-0.11 | ||
| Q4 24 | $1.85 | — | ||
| Q3 24 | $1.65 | $-0.06 | ||
| Q2 24 | $1.50 | $-0.30 | ||
| Q1 24 | $1.01 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $261.8M | $49.4M |
| Total Assets | $2.8B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
| Q4 25 | $261.8M | $49.4M | ||
| Q3 25 | $253.3M | $36.4M | ||
| Q2 25 | $240.3M | $44.5M | ||
| Q1 25 | $234.6M | $50.5M | ||
| Q4 24 | $226.4M | $55.1M | ||
| Q3 24 | $227.3M | $58.5M | ||
| Q2 24 | $218.5M | $60.4M | ||
| Q1 24 | $216.3M | $74.1M |
| Q4 25 | $2.8B | $59.0M | ||
| Q3 25 | $2.7B | $51.1M | ||
| Q2 25 | $2.7B | $60.7M | ||
| Q1 25 | $2.6B | $67.9M | ||
| Q4 24 | $2.6B | $90.6M | ||
| Q3 24 | $2.6B | $99.0M | ||
| Q2 24 | $2.5B | $107.8M | ||
| Q1 24 | $2.5B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $24.5M | $18.4M |
| Free Cash FlowOCF − Capex | $22.2M | — |
| FCF MarginFCF / Revenue | 61.8% | — |
| Capex IntensityCapex / Revenue | 6.5% | — |
| Cash ConversionOCF / Net Profit | 3.65× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $42.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.5M | $18.4M | ||
| Q3 25 | $23.4M | $-8.7M | ||
| Q2 25 | $-4.4M | $-7.5M | ||
| Q1 25 | $3.2M | $-7.5M | ||
| Q4 24 | $36.8M | $-24.0M | ||
| Q3 24 | $404.0K | $765.0K | ||
| Q2 24 | $1.7M | $-10.9M | ||
| Q1 24 | $895.0K | $-4.0M |
| Q4 25 | $22.2M | — | ||
| Q3 25 | $22.7M | — | ||
| Q2 25 | $-5.0M | — | ||
| Q1 25 | $2.9M | — | ||
| Q4 24 | $33.3M | — | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | $1.2M | — | ||
| Q1 24 | $410.0K | — |
| Q4 25 | 61.8% | — | ||
| Q3 25 | 63.0% | — | ||
| Q2 25 | -13.6% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 103.8% | — | ||
| Q3 24 | -4.9% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | 6.5% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.6% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.6% | — |
| Q4 25 | 3.65× | 1.50× | ||
| Q3 25 | 3.31× | — | ||
| Q2 25 | -0.57× | — | ||
| Q1 25 | 0.60× | — | ||
| Q4 24 | 6.09× | — | ||
| Q3 24 | 0.07× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.26× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CFFI
| Community Banking | $25.9M | 72% |
| Consumer Finance Segment | $7.0M | 19% |
| Mortgage Banking Segment | $1.9M | 5% |
| Other | $1.1M | 3% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
